Trade AstraZeneca ^AZN

Tezspire Crossing to EoE? Astrazeneca, Amgen say phase III a win

BioCryst is profitable. Now it wants to buy more rare disease drugs

AstraZeneca (LSE:AZN) Reports Positive TEZSPIRE Phase 3 Results, Is The Discount Too Wide?

AstraZeneca Stock Remains 14% Lower Despite Tezspire Phase 3 Success

Glencore and GSK mine euros for popular deals

AZN/AMGN's Tezspire Hits Primary Goal in Eosinophilic Esophagitis Study

AstraZeneca, Amgen's Tezspire Meets Co-Primary, Key Secondary Endpoints In Phase 3 EoE Trial

AstraZeneca drug succeeds in trial for swallowing disorder

Ageing, Innovation and AI: 10 Healthcare Stocks Positioned to Benefit | Financial Horse

AstraZeneca Vietnam upgrades logistics system to support growing operations

Analysts Set Astrazeneca Plc (NYSE:AZN) PT at $211.00 - Zolmax

AstraZeneca lands its largest ever euro deal

AstraZeneca prices €2.55bn euro bond sale across four tranches

Here Are Monday's Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino's Pizza, Fortune Brands, Golar LNG, Jersey Mike's Subs, Roku, and More

Towards a global collaborative approach to living guideline development in rheumatology

AstraZeneca's Earnings Beat Shows Momentum, But Can its Pipeline Deliver $80 Billion in Revenue?

AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?

AstraZeneca initiated with an Outperform at CICC

Astrazeneca Plc (NYSE:AZN) Given Consensus Rating of "Moderate Buy" by Analysts

Top Pharmaceutical Stocks To Research - August 20th - Daily Political

ET World Leaders Forum 2026: Boris Johnson thanks India for Covid vaccine, credits Brexit for UK rollout

AstraZeneca Loses Second Suit Against Medicare Drug Price Cuts

Kyntra Bio (KYNB) Q2 2026 Earnings Call Transcript

Top Pharmaceutical Stocks To Research - August 20th - Markets Daily

7,500 Shares in Astrazeneca Plc $AZN Bought by Westport Asset Management Inc.

Alpro Group partners with AstraZeneca for kidney screening initiative

Evidence-based guidelines for the diagnosis and management of adult-onset IgA vasculitis

AstraZeneca (AZN) - Research Analysts' Weekly Ratings Changes - Zolmax

Foresite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture Partner | Morningstar

AstraZeneca (LSE:AZN) Reports Positive Phase III Lung Cancer Trial Results

Here's how much a £10,000 Stocks and Shares ISA could be worth by 2035

Can AstraZeneca (LSE:AZN) Still Be A Bargain After Mixed Trial News?

Mineralys (MLYS) Q2 2026 Earnings Call Transcript

Contrasting AstraZeneca (AZNCF) and Its Rivals - Stock Observer

AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth | Morningstar

AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch

Promising Manufacturing Stocks To Research - August 17th - Zolmax

AstraZeneca (AZN) Stock Edges Higher Despite Discontinuing Phase III Lung Cancer Study

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial | Morningstar

AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda

AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer

FTSE 100 set to snap six-day losing streak as miners gain

AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review - Update | Morningstar

AstraZeneca Discontinues Phase 3 EVOLVE-Lung02 Trial Of Volrustomig In Non-small Cell Lung Cancer

Dow Jones Top Company Headlines at 5 AM ET: Alibaba to Sell Videogame Business for at Least $1.5 Billion | AstraZeneca ... | Morningstar

AstraZeneca (AZN) Stock Climbs on Promising Enhertu Cancer Trial Data

AstraZeneca ditches lung cancer treatment trial

HUTCHMED's ORPATHYS-TAGRISSO Combo Shows Significant PFS, OS Benefit In Phase III Trial

AstraZeneca To Cease EVOLVE-Lung02 Phase III Trial Of Volrustomig + Chemotherapy In MNSCLC

AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review | Morningstar

AstraZeneca lung cancer drug combination extends survival in trial

Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

AstraZeneca to discontinue late-stage lung cancer trial for volrustomig

S&CO Inc. Takes Position in Astrazeneca Plc $AZN

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing

Are Mega-Mergers Back?

Promising Manufacturing Stocks To Research - August 15th - Markets Daily

AstraZeneca (AZNCF) & Its Competitors Financial Review - Stock Observer

BMY: 2026 Pipeline And M&A Noise Will Not Mitigate Patent Cliff

Top Pharmaceutical Stocks Worth Watching - August 14th - Stock Observer

Global Drugmakers Investment: Global Drugmakers Invest $500 Billion to Enhance U.S. Manufacturing and Research, ETBrandEquity

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?

Royalty Pharma plc (RPRX) vs. AstraZeneca PLC (AZN): Which Biopharma Model Offers the Better Growth Story?

AZN: Pipeline Strength And 2030 Revenue Ambition Will Drive Re Rating

Will AstraZeneca Have to Pay Medical Expenses for Woman Injured During COVID Vaccine Trial?

Leave no one behind: optimizing kidney protection in type 1 diabetes

Royalty Pharma (RPRX) Q2 2026 Earnings Call Transcript

Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...

Beyond the Scalpel: how the PROTEUS trial redefines the role of the radical prostatectomy

AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn't Buy This Merger Talk

Hedge Funds are Bullish on AstraZeneca PLC (AZN)

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Lupin gets FDA nod for hyperkalemia drug

Astrazeneca Plc $AZN Shares Sold by NewEdge Advisors LLC

FY2026 EPS Estimates for Astrazeneca Cut by Erste Group Bank - Daily Political

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer

From RAS inhibitor resistance to rational combination strategies

Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?

Jim Cramer Highlights Pharmaceutical Giants as Non-Tech Innovation Plays Like JNJ and LLY

Lupin Gets FDA Approval for Hyperkalemia Drug | Morningstar

21 New 4-Star Stocks This Week | Morningstar

Global drugmakers invest billions to boost U.S. presence

Fasenra® (benralizumab) now approved in Canada for hypereosinophilic syndrome

Promising Pharmaceutical Stocks To Watch Now - August 10th - Daily Political

FY2027 EPS Estimates for Astrazeneca Reduced by Analyst

Type 2 diabetes prevention across the life course

Sun Pharmaceutical Industries Ltd Futures Share Price & Chart Today | IIFL Capital

Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)

Oliver Luxxe Assets LLC Purchases New Position in Astrazeneca Plc $AZN

US Economy on Stagflation Watch: Apollo Global Management's Outlook

AI Podcast: Fresh Insights on Fed Rate Cut Timing - News in a New Way

TEM stock price analysis: Why Tempus AI Stock Up Today?

FTSE 100 index near one-month lows as global sentiment sours

Moderna share price jumps as Oppenheimer upgrades stock

Week ahead: RBA poised to hike?

FTSE 100 Index: London stocks start week sharply lower

Trump's Sudden Russia Policy Shift: Rubio's Influence and Implications

Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty

September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations

Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge

Fund Managers Cautious in Q4: AI, Inflation, and Monetary Policy in Focus

US Government Shutdown Threatens October Inflation Data Release

US-EU Relations: Russia Sanctions Unite Despite Trade Tensions

BOJ Warns of Japan Stock Market Overheating, U.S. Trade Policy Risk